写的
写的
Developed in Argentina with our partners Bitgenia, our ColGenBio platform will now benefit a wider oncology patient population.
Aleksandr Bedenkov and Susana Goncalves share their thoughts on the expansion of our innovative partnership with Bitgenia to support precision medicine in Latin America.
一段时间以来，我们一直在摆脱“一种治疗方法”，以完全拥抱精密医学所提供的潜力。这是我们可以的一种方式boosttreatment outcomes, by ensuring that the right patients can receive the right medicine at the right time.
Our focus on precision medicine has been particularly evident in our A.Catalyst Network hub in Argentina, where there has been a real drive amongst healthcare professionals to accelerate the use of genomics and the latest data science technology. A precision medicine approach means treatment can be more targeted to the individual, based on more accurate diagnoses and better predictions – which, of course, gives us a greater chance of a better outcome for the patient.
根据这一运动，我们一直在与生物信息学合作伙伴Bitgenia合作开发我们的协作基因组学和生物银行平台（称为称为ColGenBio). Having originally focused on Argentina, we’ve now expanded this platform to support the whole of Latin America.
向研究人员开放重要信息
Colgenbio旨在通过使改变生活的药物与最有可能受益的患者相匹配来改善治疗结果。这是一个软件平台，旨在通过使至关重要的临床和基因组信息该地区的研究人员可供选择。
Initially focused on oncology, the platform enables clinical laboratories and researchers to access information about anonymised samples held in laboratories across Latin American countries. This information includes the different molecular genetic data that characterise each patient. Users can organise and catalogue user-loaded samples, search for samples of interest, load genomic data associated to previously studied samples, and perform statistical analysis of available genomics and patient data.
提高我们对药物和疾病的理解
Colgenbio平台为研究人员提供了急需的数据来源，以研究特定的疾病生物标志物。它旨在加强数据收集并促进实验室之间的研究合作，从而减少努力的重复。此外，我们希望它将加速采用批准和开发生物标志物，并有助于确定新指示的人群，并促进转化研究。
访问这些关键数据点不仅可以提高研究人员对药物的理解
and how they work in individual patients, but will allow organisations like ourselves to learn more about diseases. This will help us to identify potential new areas of research and make better-informed decisions about how to solve the healthcare challenges of the future.
我们坚信，Colgenbio是精确医学的重大发展。通过扩展平台以覆盖整个拉丁美洲，我们正在加速这一运动，并增强在更广泛的人群中进行研究的可能性，这最终将使患者比以往任何时候都更具创新的新疗法。
Being a part of the A.Catalyst Network has opened up a wealth of opportunities for precision medicine in Argentina and across Latin America. The ColGenBio platform provides an urgently needed source of genomic data for researchers looking at specific biomarkers for diseases. It promotes research collaboration between laboratories, reducing duplication of efforts. Additionally, we hope that it will accelerate the adoption of approved and in-development biomarkers, and help to identify populations for new indications, as well as facilitate translational research.
请访问A.Catalyst网络网页to learn more about how we are working with partners across emerging biomedical clusters to accelerate innovation, increase healthcare access and improve outcomes for society.